Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL730 IV SAD in Healthy Volunteers
NCT03375606Phase 1Terminated
- Sponsor
- CSL Limited
- Start
- Jan 2018
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial comparing CSL730 with Placebo (2 arms). Primary endpoint: Percentage of subjects with adverse events overall, and by causality and severity. Started Jan 2018; status: terminated.
02
Drugs
CSL730
Beyond the preview
Go deeper on NCT03375606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03375606.